In an effort to be more visible to the public, the FDA now publishes its own 'transparency blog". This post deals with their role in regulating orphan drugs in service of the 7000+ rare diseases.
Posted by Bruce Lehr June 22nd 2010.
« Smart Kid Explains Orphan Drugs, Pricing and Profits | Main | Which Drugmaker Does The Most For The Poor? »
06/22/2010
FDA Comments on Its Role in Rare Diseases & Orphan Drugs
| | |
TrackBack
TrackBack URL for this entry:
http://www.typepad.com/services/trackback/6a0120a77f675b970b0133f193c783970b
Listed below are links to weblogs that reference FDA Comments on Its Role in Rare Diseases & Orphan Drugs:
1 Reblog
The comments to this entry are closed.
Recent Posts
- Pharma R&D Spending vs Other Industries
- Innovation as Illustrated by Beer
- Global Biosimilar Market Report 2013
- The Outcomes Era
- Latest Myriad Case Commentary
- Pharma Need for Adapting to Change
- US Drug Market Contracts for First Time - EVER!
- R&D Spending may not be ALL Bad
- Myriad BRCA Test Cost is In-Line
- Pharma vs Society - Let's Get Ready to Stuuuummmbbble!
Search
Archives
- May 19, 2013 - May 25, 2013
- May 12, 2013 - May 18, 2013
- May 5, 2013 - May 11, 2013
- April 28, 2013 - May 4, 2013
- April 21, 2013 - April 27, 2013
- April 14, 2013 - April 20, 2013
- April 7, 2013 - April 13, 2013
- March 31, 2013 - April 6, 2013
- March 24, 2013 - March 30, 2013
- March 17, 2013 - March 23, 2013
Categories
- AIDs
- Animal Health
- Antibody Drug Conjugates
- Brazil News
- Business Model
- Cell Engineering
- China news
- Clinical Results
- CNS Therapies
- Conservative Curmudgeon Palaver
- Current Events
- Development Funding & Investment
- Drug Development
- Economics
- Ethics
- Facility News
- FDA & EU Approvals
- Gene Therapy
- Generics & Biosimilars
- Government Policy
- Healthcare Reform
- India News
- Innovation
- Korea News
- Liberal Altruisim
- Manufacturing Challenges
- Market Data & Facts & Research
- Market Rumors
- Mergers & Acquisitions
- Oncology
- OpEx and Lean
- Orphan, Neglected & Rare Diseases
- Outsourcing
- Patents & Legal
- Personalized Medicine
- Process Development
- Product Licensing/Acquisition
- Product Recalls/Warning Letters
- Quality Management Systems
- R&D Changes & Trends
- Random Fun Stuff
- Raw Material Detectives
- Raw Material Testing
- Regenerative Medicine & Stem Cells
- Regulatory Affairs & Policy
- Reimbursement & 3rd Party Payers
- Risk Mitigation
- RNAi therapeutics
- Russia News
- Science & Technology
- Supply Chain Management
- Trade Policy
- Trade Shows, Seminars, & Webinars
- Translational Medicine
- Vaccines & Virus
- Venture Capital
- Virtual Biotech's
- Weblogs & Websites
- Whitepapers
Comments